The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HRTX | -36.96% | -93.21% | -41.61% | -100% |
| S&P | +14.08% | +93.57% | +14.12% | +1,946% |
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
These two biopharma stocks could be poised for a major growth spurt.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $38.21M | 16.5% |
| Gross Profit | $26.30M | 12.6% |
| Gross Margin | 68.82% | -2.4% |
| Market Cap | $230.98M | -23.5% |
| Market Cap / Employee | $1.89M | 0.0% |
| Employees | 122 | -3.2% |
| Net Income | -$17.50M | -260.9% |
| EBITDA | -$3.18M | 18.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $43.07M | 67.3% |
| Accounts Receivable | $81.05M | 20.9% |
| Inventory | 70 | 52.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $139.66M | -20.2% |
| Short Term Debt | $0.78M | -76.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -5.78% | 6.6% |
| Return On Invested Capital | -75.97% | 7.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.33M | -54.7% |
| Operating Free Cash Flow | $1.33M | -60.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -5.80 | -9.95 | -11.09 | -7.08 | -6.12% |
| Price to Sales | 1.62 | 2.92 | 2.13 | 1.38 | -37.33% |
| Price to Tangible Book Value | -5.80 | -9.95 | -11.09 | -7.08 | -6.12% |
| Enterprise Value to EBITDA | 74.21 | 151.09 | -550.76 | -96.75 | -8.85% |
| Total Debt | $177.76M | $177.26M | $176.74M | $140.44M | -21.21% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
